Fly News Breaks for July 2, 2019
Jul 2, 2019 | 18:17 EDT
After speaking with two cataract surgeons that participated in the Dextenza sampling program, Piper Jaffray analyst Joseph Catanzaro maintains an Overweight rating on Ocular Therapeutix with an $8 price target. Both had largely positive experiences with Dextenza and no concerns around safety and efficacy, Catanzaro tells investors in a research note. Further, both indicated that they intend to offer Dextenza to as many patients as possible, adds the analyst. He thinks the commentary bodes well for Dextenza 's launch.
News For OCUL From the Last 2 Days
There are no results for your query OCUL